Introduction
Colorectal cancer (CRC) is the second-leading cause of cancer-related mortality in Europe and the United States, but early detection boosts the 5- year relative survival rate to 91%. While colonoscopy remains the gold standard for screening, its invasive nature reduces adherence. Although less invasive stool-based and emerging blood-based biomarker tests have greatly advanced screening efforts, additional strategies are needed to enhance accuracy, particularly for detecting early-stage CRC and advanced adenomas (AA). In this study, part of the Horizon Europe-funded DIOPTRA project for Mission Cancer, a blood-based protein biomarker approach to improve early detection was investigated.
Aims & Methods
A prospective clinical study was conducted to collect blood samples from individuals undergoing colonoscopy (N=260). Participants were categorized into four groups: Healthy (no findings or hyperplastic polyps), Non-AA (NAA), AA, and CRC based on the colonoscopy findings and subsequent histopathological diagnosis. Each sample was analyzed using Olink’s next-generation proteomics platform, based on the proximity extension assay technology, measuring 3,072 proteins in blood. Bioinformatic analysis, utilizing linear machine learning algorithms and differential expression methods was performed.
Results
The analysis pipeline identified a 12-protein signature capable of accurately distinguishing the four study groups. In a 5-fold cross-validation scheme, the linear combination of these proteins achieved a sensitivity of 98.1% (95% CI:[90.1%, 100.0%]) for CRC detection and a specificity of 93.1% (95% CI:[77.2%, 99.2%]) for advanced neoplasia (calculated by combining the Healthy
and NAA groups). Notably, the model’s sensitivity for stage I/II CRC was 100.0% (95% CI: [85.8%, 100.0%]) and for AA was 50.0% (95% CI: [37.0%,63.0%]), demonstrating the potential of protein signatures in blood to detect early-stage cancer and advanced precancerous lesions.
Comparison
| AUC (%)
| Sensitivity (%)
| Sensitivity 95% CI
| Specificity (%)
| Specificity 95% CI
| Accuracy (%)
| Accuracy 95% CI
|
CRC vs Normal
| 95.9
| 98.1
| 90.1-100.0
| 93.1
| 77.2-99.2
| 96.4
| 89.8-99.2
|
SI vs Normal
| 96.9
| 100.0
| 71.5-100.0
| 93.1
| 77.2-99.2
| 95.0
| 83.1-99.4
|
SII vs Normal
| 97.6
| 100.0
| 75.3-100.0
| 93.1
| 77.2-99.2
| 95.2
| 83.8-99.4 |
SI/SII vs Normal
| 97.3
| 100.0
| 85.8-100.0
| 93.1
| 77.2-99.2
| 96.2
| 87.0-99.5
|
AA vs Normal
| 78.0
| 50.0
| 37.0-63.0
| 93.1
| 77.2-99.2
| 63.7
| 53.0-73.6
|
HGD vs Normal
| 74.7
| 43.5
| 23.2-65.5
| 93.1
| 77.2-99.2
| 71.2
| 56.9-82.9
|
CIS vs Normal
| 66.4
| 50.0
| 06.8-93.2
| 93.1
| 77.2-99.2
| 87.9
| 71.8-96.6
|
AA10 vs Normal
| 85.8
| 61.1
| 35.7-82.7
| 93.1
| 77.2-99.2
| 80.9 | 66.7-90.9
|
V vs Normal
| 74.1
| 50.0
| 21.1-78.9
| 93.1
| 77.2-99.2
| 80.5
| 65.1-91.2 |
Table. The performance metrics of the 12-plex assay for different categories of CRC and AA. Normal samples are referred to Healthy + NAA. The metrics have been calculated considering disease state (CRC, AA, sub-categories) as true positives, and Normal samples as true negatives.
Results: The AI model performance of the 12-plex assay across different classifications of advanced neoplasia has outperformed the current blood-based IVD in the case of CRC (98.1% Sensitivity, 95% CI: [90.1%, 100.0%]) and AA (50.0% Sensitivity, 95% CI: [37.0%, 63.0%]), without compromising the classification of Non-neoplastic samples (93.1% Specificity, 95% CI: [77.2%, 99.2%]).
Conclusion
Future work is focused on developing multiplex immunoassays for these biomarkers to orthogonally validate the findings and assess the signature’s analytical and clinical performance in a large participant cohort from the DIOPTRA validation studies (N=1600 participants). This protein biomarker signature could pave the way for more accurate, patient-friendly CRC screening methods that detect both cancer and its precursors at earlier, more treatable stages.